Abbott joins transcatheter mitral valve replace race
This article was originally published in Clinica
Abbott Labs is jumping on the transcatheter mitral valve replacement (TMVR) bandwagon with an agreement to buy out the rest of Tendyne Holdings and an option to Cephea Valve Technologies, both announced July 30.
You may also be interested in...
Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.
Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.